Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2230|43|2|234-236

ISSN： 0307-6938

Source： CLINICAL & EXPERIMENTAL DERMATOLOGY, Vol.43, Iss.2, 2018-03, pp. : 234-236

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Patient‐reported outcomes enhance understanding of the impact of pazopanib in soft tissue sarcoma

By  

CANCER, Vol. 121, Iss. 17, 2015-09 ,pp. : 2868-2870

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Case of Classic Kaposi's Sarcoma with Multiple Organ Involvement

By  

THE JOURNAL OF DERMATOLOGY, Vol. 27, Iss. 11, 2000-11 ,pp. : 740-744

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful Treatment with Pazopanib for Multiple Lung Metastases of Inguinal Epithelioid Sarcoma: A Case Report

By  

Case Reports in Oncology, Vol. 8, Iss. 3, 2015-09 ,pp. : 378-384

Karger

Access to resources Recommend Favorite

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases

By  

Case Reports in Oncology, Vol. 9, Iss. 3, 2016-10 ,pp. : 639-643

Karger

Access to resources Recommend Favorite

Classic Kaposi's Sarcoma: A Review of 90 Cases

By  

THE JOURNAL OF DERMATOLOGY, Vol. 19, Iss. 9, 1992-09 ,pp. : 548-552

John Wiley & Sons Inc

Access to resources Recommend Favorite